Trauma Resilience and Recovery Program for Depression

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
George Washington University Hospital, Washington, VA
Depression+3 More
Trauma Resilience and Recovery Program - Behavioral
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study to learn about patients' experience with the Trauma Resilience and Recovery program (TRRP) and/or the enhanced care group.

Eligible Conditions

  • Depression
  • Post Traumatic Stress Disorder (PTSD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 22 Secondary · Reporting Duration: 3, 6, and 12-months post- baseline assessment

3, 6, and 12-months post- baseline assessment
Food Insecurity
Job Insecurity
Occupational Status
PROMIS General Life Satisfaction
PROMIS Global Health
PROMIS Sleep Disturbance
3-, 6-, and 12-months post- baseline assessment
Acceptance of Treatment Referral and Initiation of Treatment
NIDA Quick Screen; alcohol, tobacco, prescription and illicit drug use
PROMIS Pain Intensity and Interference Scale
PROMIS Self-Efficacy
Patient Health Questionnaire-9 (PHQ-9)
Stigma Scale for Receiving Psychological Help
3-months post-baseline
National Adverse Childhood Experiences Questions
Neighborhood Environment
Baseline
Demographics
Electronic Medical Record Data (EMR)
Injured Trauma Survivor Screen (ITSS)
Baseline, 3-, 6-, and 12- months post-baseline
Change from Baseline PTSD Checklist for DSM-5 8- item (PCL8-5) at 3-,6-, and 12-month
National Health Interview Survey Adult Access to Health Care and Utilization Module
PROMIS Emotional and Instrumental Support
The California Health Interview Survey (CHIS) question
The Kessler 6 (K6)
The Major Experiences and Everyday Discrimination Scale

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Enhanced Usual Care Condition
1 of 2
Trauma Resilience and Recovery Program
1 of 2
Active Control
Experimental Treatment

350 Total Participants · 2 Treatment Groups

Primary Treatment: Trauma Resilience and Recovery Program · No Placebo Group · N/A

Trauma Resilience and Recovery Program
Behavioral
Experimental Group · 1 Intervention: Trauma Resilience and Recovery Program · Intervention Types: Behavioral
Enhanced Usual Care ConditionNoIntervention Group · 1 Intervention: Enhanced Usual Care Condition · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3, 6, and 12-months post- baseline assessment
Closest Location: George Washington University Hospital · Washington, VA
Photo of washington 1Photo of washington 2Photo of washington 3
2017First Recorded Clinical Trial
1 TrialsResearching Depression
28 CompletedClinical Trials

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
828 Previous Clinical Trials
5,371,503 Total Patients Enrolled
35 Trials studying Depression
6,367 Patients Enrolled for Depression
Agency for Healthcare Research and Quality (AHRQ)FED
356 Previous Clinical Trials
6,992,193 Total Patients Enrolled
16 Trials studying Depression
12,443 Patients Enrolled for Depression
George Washington UniversityOTHER
197 Previous Clinical Trials
110,494 Total Patients Enrolled
11 Trials studying Depression
11,301 Patients Enrolled for Depression
Kenneth Ruggiero, PhDPrincipal InvestigatorMedical University of South Carolina

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.